Repligen Corporation is comprised of a therapeutics and a bioprocessing division committed to advancing the development and commercialization of pharmaceutical products.  The focus of the therapeutics business is on the development of innovative therapies which deliver value to patients and clinicians in neurology, gastroenterology and orphan diseases.  The bioprocessing division focuses on the development and commercialization of products that are used for the production of biopharmaceuticals.

Major Product Lines:

• Protein A ELISA Kits

- Therapeutic Products

• RG1068 - Pancreatic Imaging
• RG2417 - Bipolar Disorder
• RG2833 - Friedreich's Ataxia
• RG-SMA - Spinal Muscular Atrophy

- Bioprocessing

For more information visit: www.repligen.com